New-onset cutaneous lichen planus following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination
We report a 56-year-old male who developed cutaneous lichen planus (LP) following Vaxzevria (Oxford-AstraZeneca) COVID-19 vaccination. Multiple topical and systemic therapies were tried with limited success; however, partial improvement was observed with narrow-band UVB (NB-UVB) phototherapy. This r...
Saved in:
| Main Authors: | Amira Muftah, Stephen Lee, Mariam Abbas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X241307109 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Middle Cerebral Artery Dissection after AstraZeneca COVID-19 Vaccination
by: Hsin-Wei Wu, et al.
Published: (2025-04-01) -
Case report of secondary T-cell deficiency following the AstraZeneca COVID-19 vaccine
by: Amin Esmailian, BSC (Hons), MD, et al.
Published: (2024-11-01) -
Acute Inflammatory Pericarditis following First Dose of COVID-19 Vaccine (AstraZeneca)
by: Mohammed Alshaikh, et al.
Published: (2022-01-01) -
Relationships and Activities. The study is supported by OOO AstraZeneca Pharmaceuticals.
by: E. V. Shlyakhto, et al.
Published: (2023-07-01) -
Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts
by: Sorawit Chittrakarn, et al.
Published: (2024-12-01)